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- cancelation of any chance of cure 
in the active surveillance arm, 
even if such cure is limited with 
13.1 ± 1.7% patients free of dis-
ease at 4 years after radiofrequency 
ablation (RFA) in our series of 566 
patients with 1037 lung metastases.3
Concerning the “moderate efﬁ-
cacy” of cryoablation describe by 
Dr. Macbeth, we report 1-year efﬁcacy of 
94.2% with cryoablation1 and 89% at 4 
years with RFA,3 which is in the range to 
what usually reported after surgical resec-
tion.4 Concerning safety of cryoablation, 
no major side effects were recorded, and 
most common side effect was pneumo-
thorax requiring small bore chest tube 
placement in 18.8% of patients with tube 
retrieval at day 1 or 2 after treatment.1 
This compares favorably with surgery 
requiring large bore chest tube insertion 
in all patients with later retrieval.
Trying to answer the question of 
Dr. Treasure, “Is cryoablation of lung 
metastases a justiﬁable procedure?,” 
the ﬁrst answer is that we are convinced 
that minimal-invasive ablation tech-
niques including cryotherapy or RFA 
are more justiﬁable than surgery due to 
their high efﬁcacy and low morbidity, 
thus avoiding “the inevitable downside 
of pain of thoracotomy and, with larger 
resections, loss of lung function” as 
describe elsewhere by Dr. Treasure.2 
Then, even in a randomized trial as 
suggested by Dr. Macbeth, it might 
be difﬁcult to “see the signal from the 
noise with the inevitable use of combi-
nations of therapies making it impos-
sible to discern the effect of surgery on 
survival” as explain by Dr. Treasure.2 
Percutaneous ablation might provide 
the gain of complete control of the 
disease and avoid the inevitable down-
side of surgery and replace surgery 
for small size metastases in a selected 
population. We do think that cryoabla-
tion of lung metastases is a justiﬁable 
procedure when trying to approach 
individual patients care when there is 
lack of level I evidence.
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for trying to ablate a few radiologically 
detectable pulmonary metastases.
Although there is insufﬁcient evi-
dence that removing lung metastases 
by any modality improves survival, is it 
good palliation? Patients selected for sur-
gical metastasectomy have almost always 
been asymptomatic. It is unusual for lung 
metastases to contribute to symptoms 
near the end of life or to contribute to 
the mode of death. This study shows that 
cryotherapy is not a harmless treatment. 
One in ﬁve patients had a postprocedural 
pneumothorax. The information in this 
small series of patients is insufﬁcient to 
assess other complications, but it is likely 
that they will suffer some of the effects of 
cavitating lung disease including infec-
tion and hemoptysis.
On the available evidence, removal 
or ablation of asymptomatic lung metas-
tases by any modality cannot be justiﬁed 
for survival or palliation. The oncologi-
cal community should not accept it as 
“standard” but should collaborate in ran-
domized trials to assess its effectiveness.
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In reply:
We thank Dr. Macbeth and his 
coworkers for the interest they placed 
in reading our publication in Journal of 
Thoracic Oncology1 and greatly appre-
ciated their comments. We do agree 
that there is no level I evidence of ben-
eﬁt of lung metastasectomy for overall 
survival, although many large series 
suggest that a beneﬁt might exist. A 
randomized control trial as Pulmonary 
Metastasectomy in Colorectal Cancer2 
is an interesting way to try to answer the 
question of beneﬁt in terms of overall 
survival, but the randomization between 
lung metastasectomy and active surveil-
lance in the PULMICC study has limi-
tations such as the following:
- recruitment, because it is difﬁcult 
for a patient accessible to surgery 
that the choice in between surgery 
and no treatment will be made 
after “flipping a coin,” and this is 
probably one of the reason why 
PULMICC study is recruiting 
slowly.
- deﬁnition of what is active surveil-
lance and when to treat a patient 
under active surveillance? Is it pos-
sible/ethical to refuse surgery in the 
active surveillance arm? What about 
a single lung metastasis that grows 
from 1.5 to 3.5 cm in 18 months, 
remains single location of disease 
and is now abutting the pleura? Will 
we be really able to measure the 
beneﬁt of active surveillance when 
crossover is unavoidable?
- difﬁculty in measuring possible ben-
eﬁt of resection or ablation to the 
patient beside overall survival. What 
is the beneﬁt of being disease free for 
a mean of 10 months after ablation?
DOI: 10.1097/JTO.0000000000000695
Copyright © 2015 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/15/1012-e121
e122 Copyright © 2015 by the International Association for the Study of Lung Cancer
Letters to the Editor Journal of Thoracic Oncology ® • Volume 10, Number 12, December 2015
Successful AZD9291 
Therapy Based on 
Circulating T790M
REfERENCES
 1. Lindeman NI, Cagle PT, Beasley MB, et al. 
Molecular testing guideline for selec-
tion of lung cancer patients for EGFR 
and ALK tyrosine kinase inhibitors: 
guideline from the College of American 
Pathologists, International Association for 
the Study of Lung Cancer, and Association 
for Molecular Pathology. J Mol Diagn 
2013;15:415–453.
 2. Jain D, Mathur SR, Iyer VK. Cell blocks in 
cytopathology: a review of preparative meth-
ods, utility in diagnosis and role in ancillary 
studies. Cytopathology 2014;25:356–371.
 3. Henwood AF, Charlton A. Extraneous epithe-
lial cells from thromboplastin in cell blocks. 
Cytopathology 2014;25:412–413.
 4. Choi SJ, Choi YI, Kim L, et al. Preparation of 
compact agarose cell blocks from the residues 
of liquid-based cytology samples. Korean J 
Pathol 2014;48:351–360.
 5. Pathak AK, Bhutani M, Kumar S, Mohan 
A, Guleria R. Circulating cell-free DNA in 
plasma/serum of lung cancer patients as a 
potential screening and prognostic tool. Clin 
Chem 2006;52:1833–1842.
better morphological assessment of 
the malignant cell population and per-
mits immunohistochemsitry.2 This is 
the preferred method to prepare cell 
blocks worldwide.2–4 Current molecu-
lar pathology guidelines from the 
College of the American Pathologists, 
International Association for the Study 
of Lung Cancer, and the Association for 
Molecular Pathology recommend the 
use of cell blocks for molecular testing 
and therapy selection criteria for epi-
dermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors and anaplas-
tic lymphoma kinase inhibitors.1
Plasma of course contains cell-
free DNA.5 Plasma sources vary between 
laboratories (human, rabbit, etc.) as does 
the volume of plasma used to form cell 
blocks.3,4 To identify the level of DNA 
contamination in cell blocks, we have 
analyzed DNA extracted from cell-free 
plasma thrombin cell blocks and blank 
(tissue free) histological parafﬁn blocks 
using routine molecular techniques includ-
ing an in-house PCR/Pyrosequencing 
and a Qiagen Therascreen EGFR RGQ 
PCR Kit. DNA product was detected in 
the elute extracted from the empty cell 
blocks; however, no DNA was detected in 
the control parafﬁn blocks.
We conclude that plasma is a source 
of contaminating DNA. Fortunately, a 
review of our molecular assays performed 
on cell blocks found no evidence of false-
positive or false-negative results. As high 
throughput Next Generation Sequencing 
platforms make their way into routine 
diagnostic practice, their superior sensi-
tivity in DNA mutation detection in the 
presence of any extraneous DNA might 
generate false-positive results and impact 
on the molecular diagnosis. Given the 
potential for extraneous DNA to affect 
molecular assays, we believe that the 
plasma thrombin clot technique should 
no longer be used when molecular testing 
is to be undertaken, and that pathology 
laboratories should change their process-
ing techniques accordingly.
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To the Editors:
Molecular testing to personalize 
therapy is an essential part of the investi-
gation of cancer to personalize anticancer 
therapy.1 Availability of sufﬁcient tissue 
is important, and in some settings, for 
example, lung cancer diagnosed by bron-
choscopic biopsy or ultrasound guided 
cytology, this may be challenging.
For cytological specimens, resid-
ual material remaining after the initial 
diagnostic slide can be made into a 
cell block. In most pathology labo-
ratories, these are prepared by using 
plasma to form a clot entrapping the 
cells followed by embedding into par-
afﬁn wax. Sections from this allow 
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To the Editor:
The epidermal growth factor receptor 
(EGFR) gatekeeper mutation T790M is 
associated with resistance against ﬁrst- 
and second-generation EGFR tyro-
sine kinase inhibitors in patients with 
advanced non–small-cell lung cancer.1 
The third-generation inhibitor AZD9291 
can overcome T790M-mediated resis-
tance in patients, as shown by a recent 
clinical trial.2 T790M can be detected 
in tumor tissue, circulating tumor cells, 
and circulating tumor DNA.3–5 Here, we 
report on a ﬁrst patient with AZD9291 
therapy based on circulating T790M.
In 2015, we established an IRB-
approved research collaboration with 
NEO New Oncology AG (Cologne, 
